[go: up one dir, main page]

WO2010023658A3 - Compositions and methods for the treatment of glioblastoma - Google Patents

Compositions and methods for the treatment of glioblastoma Download PDF

Info

Publication number
WO2010023658A3
WO2010023658A3 PCT/IL2009/000809 IL2009000809W WO2010023658A3 WO 2010023658 A3 WO2010023658 A3 WO 2010023658A3 IL 2009000809 W IL2009000809 W IL 2009000809W WO 2010023658 A3 WO2010023658 A3 WO 2010023658A3
Authority
WO
WIPO (PCT)
Prior art keywords
glioblastoma
treatment
compositions
methods
relates
Prior art date
Application number
PCT/IL2009/000809
Other languages
French (fr)
Other versions
WO2010023658A2 (en
Inventor
David Givol
Gideon Rechavi
Nitzan Rosenfeld
Original Assignee
Rosetta Genomics Ltd.
Tel Hashomer Medical Infrastructure And Services Ltd.
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosetta Genomics Ltd., Tel Hashomer Medical Infrastructure And Services Ltd., Yeda Research And Development Co. Ltd. filed Critical Rosetta Genomics Ltd.
Publication of WO2010023658A2 publication Critical patent/WO2010023658A2/en
Publication of WO2010023658A3 publication Critical patent/WO2010023658A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates in general to microRNA molecules associated with glioblastoma, as well as various molecules relating thereto. More specifically, the invention relates to methods and compositions for the treatment of glioblastoma and for treatment by a combination of microRNA molecules and Imatinib mesylate.
PCT/IL2009/000809 2008-08-28 2009-08-18 Compositions and methods for the treatment of glioblastoma WO2010023658A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13631808P 2008-08-28 2008-08-28
US61/136,318 2008-08-28
US16716609P 2009-04-07 2009-04-07
US61/167,166 2009-04-07

Publications (2)

Publication Number Publication Date
WO2010023658A2 WO2010023658A2 (en) 2010-03-04
WO2010023658A3 true WO2010023658A3 (en) 2010-05-06

Family

ID=41327619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2009/000809 WO2010023658A2 (en) 2008-08-28 2009-08-18 Compositions and methods for the treatment of glioblastoma

Country Status (1)

Country Link
WO (1) WO2010023658A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BANDRES E ET AL: "Expression of microRNA-451 is associated with disease-free survival in gastric cancer patients treated with chemoradiotherapy after gastric resection", EJC SUPPLEMENTS, vol. 5, no. 4, September 2007 (2007-09-01), & 14TH EUROPEAN CANCER CONFERENCE (ECCO 14); BARCELONA, SPAIN; SEPTEMBER 23 -27, 2007, pages 90, XP002558069, ISSN: 1359-6349 *
GODLEWSKI JAKUB A ET AL: "MicroRNA based regulation of glioma cell migration - the role of miR-451", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 49, April 2008 (2008-04-01), & 99TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; SAN DIEGO, CA, USA; APRIL 12 -16, 2008, pages 77 - 78, XP002558068, ISSN: 0197-016X *
NICKL-JOCKSCHAT T ET AL: "An imbalance between Smad and MAPK pathways is responsible for TGF-beta tumor promoting effects in high-grade gliomas.", INTERNATIONAL JOURNAL OF ONCOLOGY FEB 2007, vol. 30, no. 2, February 2007 (2007-02-01), pages 499 - 507, XP002558071, ISSN: 1019-6439 *
PICCIRILLO S G M ET AL: "Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells", NATURE (LONDON), vol. 444, no. 7120, December 2006 (2006-12-01), pages 761 - 765, XP002558070, ISSN: 0028-0836 *
SHI LEI ET AL: "hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells.", BRAIN RESEARCH 21 OCT 2008, vol. 1236, 30 July 2008 (2008-07-30), pages 185 - 193, XP002558067, ISSN: 0006-8993 *
SILBER JOACHIM ET AL: "miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.", BMC MEDICINE 2008, vol. 6, 24 June 2008 (2008-06-24), pages 14, XP002558066, ISSN: 1741-7015 *

Also Published As

Publication number Publication date
WO2010023658A2 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
IL232094A0 (en) Fibronectin type iii domain based scaffold compositions, methods and uses
PL2583959T3 (en) Integrated process to produce 2,3,3,3-tetrafluoropropene
IL215936A0 (en) Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2009039307A3 (en) Hydrogels and methods for producing and using the same
SG155871A1 (en) Conjugated diene polymer, conjugated diene polymer composition, and process for producing conjugated diene polymer
SG159478A1 (en) CONJUGATED DIENE POLYMER, CONJUGATED DIENE POLYMER COMPOSITION, AND METHOD FOR PRODUCING CONJUGATED DIENE POLYMER Abstract:
MX301000B (en) Ethanol production by microorganisms.
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
WO2010078900A3 (en) Novel aliphatically substituted pyrazolopyridines, and the use thereof
EP2281058A4 (en) Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
ZA201005278B (en) Folates, compositions and uses thereof
EP2282735A4 (en) Compounds, compositions and methods for making the same
WO2009158719A3 (en) Methods and compositions for treating disorders
WO2009102569A3 (en) Cell lines and methods for making and using them
WO2009007535A3 (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
WO2011079307A3 (en) Methods and compositions for treating neurological disorders
CL2008000980A1 (en) DOCETAXEL ANHYDRA CRYSTAL FORM; PREPARATION METHOD, USEFUL AS AN ANTITUMORAL.
EP2285953A4 (en) Rna polyphosphatase compositions, kits, and uses thereof
WO2010023658A3 (en) Compositions and methods for the treatment of glioblastoma
PL2262828T3 (en) Compositions, methods and kits
WO2011037712A3 (en) Nutritional compositions including theanine and exogenous nucleotides
WO2009053742A3 (en) Salts of nefopam and their use in therapy
WO2008057681A3 (en) Thiophene compounds
WO2009088939A3 (en) Compositions and methods for treating neurodegenerative diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09787538

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09787538

Country of ref document: EP

Kind code of ref document: A2